liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Hematologiska kliniken US.
Kristianstad Central Hospital, Sweden.
Vise andre og tillknytning
2015 (engelsk)Inngår i: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 39, nr 1, s. 33-37Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.

sted, utgiver, år, opplag, sider
Elsevier , 2015. Vol. 39, nr 1, s. 33-37
Emneord [en]
Adverse reaction; Chronic lymphocytic leukemia; Rituximab; Therapy
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-114250DOI: 10.1016/j.leukres.2014.09.019ISI: 000346858200005PubMedID: 25499233OAI: oai:DiVA.org:liu-114250DiVA, id: diva2:788637
Merknad

Funding Agencies|Roche Sweden AB [ML22754]

Tilgjengelig fra: 2015-02-16 Laget: 2015-02-16 Sist oppdatert: 2017-12-04

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed
Av organisasjonen
I samme tidsskrift
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 89 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf